Products
Opicinumab Biosimilar Monoclonal Antibody (LINGO1) for Research
Pre-Made Opicinumab biosimilar, Whole mAb, Anti-LINGO1 Antibody: Anti-LERN1/LRRN6A/MRT64/UNQ201 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Opicinumab (BIIB033) is a fully human monoclonal antibody designed for the treatment of multiple sclerosis, acute optic neuritis (AON), and other associated demyelinating diseases. A biologic drug, it is designed to function as a LINGO-1 protein antagonist, known as “Anti-Lingo-1”.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-407-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Opicinumab biosimilar, Whole mAb, Anti-LINGO1 Antibody: Anti-LERN1/LRRN6A/MRT64/UNQ201 therapeutic antibody |
| INN Name | Opicinumab |
| Target | LINGO1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 4oqt:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Biogen Idec;Dyax;Biogen |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Multiple sclerosis;Optic neuritis |
| Development Tech | Dyax Human Phage Display |
About target - LINGO1
1. Protein Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1
2. Gene LINGO1
3. Organism Homo sapiens (Human)
Function
Functional component of the Nogo receptor signaling complex (RTN4R/NGFR) in RhoA activation responsible for some inhibition of axonal regeneration by myelin-associated factors (PubMed:14966521, PubMed:15694321).
Is also an important negative regulator of oligodentrocyte differentiation and axonal myelination (PubMed:15895088).
Acts in conjunction with RTN4 and RTN4R in regulating neuronal precursor cell motility during cortical development (By similarity).
